Canopy Growth posts 13% revenue gain but cash burn deepens, investors unmoved
The cannabis sector has spent years resetting investors' expectations, one restructuring cycle at a time. Canopy Growth (NASDAQ: CGC) posted fiscal first-quarter revenue of $58.9 million, a 13% year-over-year gain for the period…
Key takeaways
- Canopy Growth reported fiscal first-quarter revenue of $58.9 million, a 13% year-over-year gain for the period ended June 30.
- Adjusted gross margin expanded to 31% from 25%, and adjusted EBITDA loss narrowed 59% to $2.3 million.
- Free cash outflow widened to $18.6 million from $8.4 million a year earlier, while net loss was $10.6 million.
- Portions of the Canadian medical and adult-use growth came from the MTL Cannabis acquisition, so the 13% gain was not purely organic.
- The stock barely reacted, as investors focused on deepening cash consumption rather than the revenue and margin improvements.
The cannabis sector has spent years resetting investors' expectations, one restructuring cycle at a time. Canopy Growth (NASDAQ: CGC) posted fiscal first-quarter revenue of $58.9 million, a 13% year-over-year gain for the period ended June 30, and found the market's patience still running thin. The stock barely reacted.
The margin story moved in the right direction. Adjusted gross margin expanded to 31% from 25% in the year-ago period, and the adjusted EBITDA loss narrowed 59% to $2.3 million. Canadian medical cannabis revenue rose 22%, adult-use sales added 10%, and international cannabis revenue grew 10%.
The cash problem
Those gains land alongside a sharper deterioration at the cash level. Net loss for the quarter came to $10.6 million, and free cash outflow widened to $18.6 million from $8.4 million a year earlier. For a business that has covered its funding gap through years of restructuring and repeated share issuance, that directional move in cash consumption is the number the market was actually reading.
There is an additional wrinkle in the revenue line. Canopy specifically attributed portions of both its Canadian medical and adult-use growth to the MTL Cannabis acquisition. The 13% year-over-year gain therefore does not represent a clean return to organic double-digit growth. For investors calibrating how much to reward management, the source of growth matters as much as its pace.
The sector cycle
Against the backdrop of a cannabis industry that has cycled through multiple restructuring rounds without delivering durable free cash generation, Canopy's quarter occupies familiar ground. The company has a history of nascent recoveries that stopped short of operational self-sufficiency, and investors appear to be pricing that track record rather than the latest trajectory.
What the market was looking for was evidence that Canopy's operations can eventually support themselves without continuously consuming capital. The results suggest the business is moving in that direction. But for the stock to become more interesting, the free cash outflow trajectory needs to reverse. Revenue growth and margin improvement are already moving. Canopy has funded prior shortfalls through share issuance, and each return to that mechanism carries a dilution cost that extends the timeline for existing shareholders. The prior year's $8.4 million outflow pace is the benchmark the market is waiting for Canopy to approach again.
Related reading
- China's $54 billion bank and insurer recapitalization fails to move sector stocks
- Voya Financial (VOYA) Q2 2026 earnings: headline income fell while retirement and fee assets expanded
- Matthews International cuts revolving credit to $650 million and secures leverage covenant relief through December 2027
Source · 來源